Antiviral effects of foscarnet and ganciclovir therapy on human immunodeficiency virus p24 antigen in patients with aids and cytomegalovirus retinitis Journal Article

  


Authors: Studies of Ocular Complications of AIDS Research Group (SOCA); AIDS Clinical Trials Group (ACTG)
Contributors: Heinemann, M.; Polsky, B.; Squires, K.; Wise-Campbell, S.
Article Title: Antiviral effects of foscarnet and ganciclovir therapy on human immunodeficiency virus p24 antigen in patients with aids and cytomegalovirus retinitis
Abstract: To examine whether the prolonged survival seen in patients treated with foscarnet compared with those treated with ganciclovir was due to a direct effect on human immunodeficiency virus (HIV) replication, HIV p24 antigen was measured. Of 71 receiving foscarnet, 54% were p24 antigenpositive at enrollment (vs. 44% of 79 receiving ganciclovir). By immune complex-dissociated (ICD) p24 antigen analysis, 87% and 78%, respectively, were positive. After 1 month of treatment, there was a significant decline in standard (mean decline, 10.1 pglmL) and ICD (mean, 39.6 pg/mL) p24 antigen in both groups (P =.0001). Mortality was greater in those who were ICD p24 antigenpositive than in those -negative at baseline (P =.03) and in subjects with an increase in ICD p24 antigen than in those with a decline (P =.09). Thus, each drug had a suppressive effect on circulating p24 antigen, which was predictive of improved survival. The inhibitory effect on CMV replication may have a beneficial effect on limiting HIV replication. © 1995 The University of Chicago.
Keywords: adult; controlled study; survival rate; unclassified drug; major clinical study; clinical trial; drug efficacy; human immunodeficiency virus infection; follow-up studies; controlled clinical trial; randomized controlled trial; risk factors; time factors; survival time; probability; antigen detection; homosexuality, male; human immunodeficiency virus; virus replication; recombinant granulocyte colony stimulating factor; foscarnet; ganciclovir; cytomegalovirus; recombinant granulocyte macrophage colony stimulating factor; antiviral activity; virus inhibition; aids-related opportunistic infections; retinitis; hiv antibodies; aids related complex; antigen-antibody complex; humans; human; male; female; priority journal; article; cytomegalovirus retinitis; antigen p24; hiv core protein p24; regramostim
Journal Title: Journal of Infectious Diseases
Volume: 172
Issue: 3
ISSN: 0022-1899
Publisher: Oxford University Press  
Date Published: 1995-09-01
Start Page: 613
End Page: 621
Language: English
DOI: 10.1093/infdis/172.3.613
PUBMED: 7658051
PROVIDER: scopus
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-0029134046&doi=10.1093%2finfdis%2f172.3.613&partnerID=40&md5=d5e11a3219d81e8a76f8b726575f03d3
Notes: Article -- Export Date: 28 August 2018 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Murk-Hein Heinemann
    39 Heinemann
  2. Bruce Polsky
    69 Polsky
Related MSK Work